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Spinal Metastases Due to Thyroid Carcinoma:
An Analysis of 202 Patients
Yevgeniya S. Kushchayeva,1,2 Sergiy V. Kushchayev,3,4 Nancy M. Carroll,2 Erin A. Felger,2
Thera P. Links,5 Oleg M. Teytelboym,3 Franc¸oise Bonichon,6 Mark C. Preul,4 Volker K.H. Sonntag,4
Douglas Van Nostrand,7 Kenneth D. Burman,8 and Lisa M. Boyle9
Background: Spinal metastases (SMs) due to thyroid cancer (TC) are associated with significantly reduced
quality of life. The goal of this study is to analyze the clinical manifestations, presentation, and treatments of TC
SMs, and to describe specific features of SMs associated with different TC types.
Patients and Methods: A retrospective analysis of 202 TC SM patients treated at Medstar Washington Hospital
Center (37) and collected from the literature (165) was performed.
Results: The mean age of patients with SMs was 56.9– 14.7 years, and the female-to-male ratio was 2.1:1. Of
all patients, 29% (28% of follicular thyroid cancer [FTC] and 37% of papillary thyroid cancer [PTC]) had SMs
only. Twenty-nine percent of all patients and 54% of patients with single-site SMs had neither bone non-SMs
nor solid organ metastases at the time of presentation. Thirty-five percent of patients had SMs as an initial
presentation of TC. TC patients presenting with SMs had a lower rate of other bone and visceral involvement
compared with patients whose SMs were diagnosed at the time of thyroid surgery or during follow-up
( p < 0.05). SMs were more often the initial manifestation of FTC (41% vs. 24%), while PTC SMs were more
commonly diagnosed after TC diagnosis (76% vs. 59%; p< 0.05). PTC SMs were more frequently diagnosed as
synchronous (63% vs. 36% in FTC) versus FTC SMs that developed as metachronous metastases (64% vs. 37%
in PTC; p< 0.01). All FTC SMs developed within 82 (0–372) months and all PTC SMs within 35 (0–144)
months ( p< 0.01). In FTC SMs as TC manifestation, solid organ metastases involvement was less common than
in FTC SMs that were found after TC diagnosis (34% vs. 67%; p< 0.01); multisite FTC SMs compared to
solitary FTC SMs were associated with the development of other bone nonspinal metastases (82% vs. 30%;
p< 0.01) and solitary organ metastases (65% vs. 41%; p< 0.01). These correlations were not observed in PTC
SMs. FTC patients often had neural structure compression (myelopathy/radiculopathy; 72% vs. 36% in PTC),
while PTC patients frequently were asymptomatic (38% vs. 5% in FTC; p< 0.01). FTC SMs more commonly
were 131I-avid ( p < 0.01). FTC patients required surgery more frequently (72% vs. 55% in PTC; p< 0.05).
Conclusions: Our study reveals that a significant part of TC SMs patients have solitary spinal involvement at
the time of presentation and may be considered for aggressive treatment with the intention to improve quality of
life and survival. FTC SMs and PTC SMs appear to have distinct presentations, behavior, and treatment
modalities, and should be categorized separately for treatment and follow-up planning.
Introduction
In most instances, thyroid carcinoma (TC) presents asan indolent tumor and is usually associated with relatively
favorable long-term survival (1). However, when distant
metastases occur, the overall survival rate is only 40% after
10 years (1,2). Distant metastases are the most frequent cause
of TC-related death (2,3).
Spinal metastases (SM) are the most common site of TC
bone metastases, developing in more than 3% of patients with
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TC (4). Thyroid SMs differ from the SMs of other primary
cancers. Thyroid SMs have the most favorable prognosis,
with an average survival of 33.1 months compared to an
approximately seven-month survival for patients with SM
from primary tumors other than TC (2,5,6). Despite the rel-
atively favorable prognosis, patients with thyroid SMs often
have a significantly reduced quality of life, for example pain,
neurological problems, and increased mortality (2,4). In most
studies, SMs secondary to TC are analyzed within groups of
patients with other primary tumors or TC bone metastases,
making the singular clinical outcome of TC SMs difficult
to assess. There is a lack of research addressing the specific
features of SMs originating from different TC types. Most
of the literature on TC SMs is based on small sample size
publications, such as case reports, case series, or a subset of
patients in larger groups of patients with different primary
tumors where the numbers of patients with TC metastases is
invariably low or SMs are a subset of bone metastases.
The aim of this study was to perform a comprehensive
analysis of the clinical manifestations, presentation, and
treatment ofTCSMs, aswell as to describe the specific features
of SMs associated with different TC types. Therefore, we ret-
rospectively analyzed 202 patients who suffered SMs sec-
ondary to TC, 37 of whom were treated at the Medstar
Washington Hospital Center (WHC). The data of the remain-
ing 165 patients were collected from previous publications.
Materials and Methods
We reviewed the Medstar WHC database and identified 37
patients with TC SMs. This study was approved by the
Medstar WHC Institutional Review Board. We searched the
following databases for studies on TC and SMs using all
relevant keyword variations: PubMed, Cochrane Library,
Web of Science, Google Scholar, and Science Direct. A total
of 56 studies published from 1981 to 2012 were located and
systematically analyzed (2,7–61). Research completed more
than 20 years ago was excluded from our study because the
methods used at that time for diagnosis and treatment differ
from the current approaches, for example computed tomo-
graphy (CT) was not used for SMs in those days. As a result,
data from 202 patients with SMs were collected and analyzed
in the present study. Previously published patient data from
the University of Groningen (Groningen, The Netherlands)
and the Bergonie´ Institute (Bordeaux, France) published
previously were updated, and important information was
added for analysis by this study’s co-authors (TL and FB).
An analysis of the literature identified two patterns of
SMs: the initial presentation of TC as SMs (Group S; ‘‘spinal
manifestation’’), and SMs that were identified at the time or
developed after TC diagnosis (Group T; ‘‘thyroid manifesta-
tion’’ of TC).According to the time interval fromTCdiagnosis
to the detection of SMs, metastases were classified into two
types: synchronous and metachronous. Synchronous metasta-
ses were identified as metastases that were apparent at the time
of TC presentation or within six months following diagnosis,
while metachronous metastases were defined as metastases
that had developed more than six months after TC diagnosis.
Because selected manuscripts were published from various
clinical departments and different aspects of the SMs were
described with missing data and follow-up information, all
analyses and calculations of particular characteristics were
performed depending on the availability of details about the
patients. Chi-square methods, the dispersing method (F), and
the Student’s method (t-test) were used for the statistical
analysis of the cancer-related variables.
Results
General characteristics of thyroid cancer
spinal metastases
Demography. Among the 202 patients selected for the
study, 41% were males and 59% were female. The patients’
mean age at the time of TC presentation was 56.9 – 14.7
years. In terms of the primary histological classification, 63%
of the patients presented with follicular TC (FTC), 28% with
papillary TC (PTC), 5% with medullary TC (MTC), 3% with
Hu¨rthle cell carcinoma (HCC), and 1% with anaplastic TC
(ATC; Fig. 1). The status of the distant metastases other than
SMs was available in for 142 patients: 37% had both bone
non-SMs and solid organ metastases, 22% had other bone
non-SMs, 12% had solid organ metastases, and 29% had
neither bone non-SMs nor solid organ metastases. Single-site
SMs were found in 49% of the patients, and 51% of the
patients had multisite involvement (two or more vertebrae
involved). Importantly, 54% of all the TC patients with
single-site SMs did not have any other distant metastases. A
summary of the patients’ demographics, clinical features,
histology, and treatments modalities is shown in Table 1. The
mean follow-up was 42 months (0–191 months).
Clinical presentation. The initial presentation of TC as
SMs (Group S) was found in 35% of the patients. SMs that
were identified at the time of the initial diagnosis of TC or
that developed after TC diagnosis (Group T) were evident in
65% of the patients (Fig. 2).
TC with spinal manifestations (Group S). Vertebral in-
volvement can occur due to the direct spreading of TC (direct
FIG. 1. The primary histological classification of thyroid
spinal metastases. One hundred and twenty (63%) patients
had FTC, 54 (28%) had PTC, 9 (5%) with MTC, 6 (3%) had
HCC, and 2 (1%) had ATC (11 patients had tumor of un-
known histology).
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involvement) with a subsequent extension into the spinal
canal, or as the indirect (hematogeneous/lymphogeneous)
spreading of malignant cells. All three cases of direct spread
of TC into the spinal canal occurred in patients with PTC. All
had spinal cord compression and died soon after their neu-
rological symptoms manifested.
TC with thyroid manifestations (Group T). Synchronous
metastases were found in 46% of patients in Group T (30% of
all TC patients), and metachronous metastases were diag-
nosed in 54% of patients in Group T (35% of all TC patients).
When Group S, Group T synchronous SMs, and Group T
metachronous SMs were compared, bone non-SMs and solid
organ metastases were less common in Group S and more
prevalent in Group T metachronous SMs ( p < 0.05; Fig. 2).
Diagnosis of SMs. As many as 57% of the patients pre-
sented with symptoms of neuronal structure compression,
including spinal cord compression (myelopathy with or
without root compression) in 45% and root compression
(radiculopathy) in only 12% of patients. Back pain was found
to be an initial symptom in 28% of patients. The remaining
15% of patients were asymptomatic, and their metastases
were found during routine evaluation at the time of the initial
diagnosis or at the subsequent follow-up.
The patients were diagnosed with SMs by 131I whole body
scan, CT, magnetic resonance imaging (MRI), or positron
emission tomography (PET). The 131I uptake by SMs was
analyzed in 82 patients. Affected vertebral lesions that could
be distinguished from other spinal lesions and which had
localization proven via CT and/or MRI were assessed.
Overall, 180 lesions were evaluated. Of these, 58% were 131I
avid, while 42% were negative.
Treatment of the primary TC. Of 151 patients, 131 (87%)
underwent a total thyroidectomy upon TC diagnosis. Eleven
Table 1. Demographics, Clinical, Pathological Stage, and Treatment Characteristics














Males 81 (41%) 41 (34%) 29 (55%) 3 (33%) 3 (50%) 2 (100%)
Females 118 (59%) 79 (66%) 24 (45%) 6 (67%) 3 (50%) 0
Female:male ratio 2.1:1 1.9:1 0.8:1 3:1 1:1 0:2
Mean age, years 56.9 – 14.7 56.7 – 14.4 57.8 – 13.9 49.3 – 15 64.7 – 5.7 60– 21
Vertebral lesions:
Mean vertebral lesions per patient 1.91 1.94 1.91 3.2 1.5 3.0
Solitary spinal metastases 95 (49%) 46 (47%) 24 (46%) 2 (28%) 3 (50%) 0
Multiple spinal metastases 99 (51%) 60 (53%) 28 (54%) 5 (72%) 3 (50%) 2 (100%)
Metastases:
Spinal metastases only 41 (29%) 24 (28%) 16 (37%) 1 (14%) 1 (25%) 0
Spinal metastases and bone nonspinal metastases 31 (22%) 21 (24%) 9 (21%) 0 1 (25%) 0
Spinal metastases and solid organ metastases 17 (12%) 12 (14%) 5 (12%) 0 1 (25%) 0
Spinal metastases, bone nonspinal metastases,
and solid organ metastases
53 (37%) 29 (34%) 13 (30%) 6 (86%) 1 (25%) 1 (100%)
Group S (Spinal metastases as a manifestation
of thyroid cancer)
55 (35%) 43 (41%) 10 (24%) 1 (20%) 1 (17%) 0
Group T (Spinal metastases developed at the time
of thyroid cancer diagnosis or during follow-up)
103 (65%) 61 (59%) 32 (76%) 4 (80%) 5 (83%) 2 (100%)
Group T—synchronous metastases 42 (46 %) 17 (36%) 20 (63%) 1 (25%) 1 (25%) 2 (100%)
Group T—metachroneous metastases 50 (54%) 30 (64%) 12 (37%) 3 (75%) 3 (75%) 0
Mean time between thyroid cancer and spinal
metastases developing (Group T), months
128 34 152 98 0.5
Order of distant metastases appearance:
Initial bone metastases 77 (72%) 52 (81%) 23 (64%) 0 2 (50%) NA
Initial solid organ metastases 5 (5%) 3 (5%) 2 (5%) 0 NA
Initial bone metastases and solid organ
metastases
24 (23%) 9 (14%) 11 (31%) 1 (100%) 2 (50%) NA
Clinical presentation:
Myelopathy 67 (45%) 51 (57%) 13 (28%) 1 (20%) 2 (33%) NA
Radiculopathy 18 (12%) 13 (15%) 4 (9%) 0 1 (17%) NA
Back pain 42 (28%) 21 (23%) 12 (25%) 4 (80%) 2 (33%) NA
Asymptomatic 23 (15%) 4 (5%) 18 (38%) 0 1 (17%) NA
SMs treatments:
Surgery 122 (67%) 83 (72%) 26 (55%) 4 (50%) 2 (33%) 1 (50%)
Conservative treatment 45 (24%) 21 (18%) 13 (28%) 4 (50%) 4 (67%) 1 (50%)
Radiosurgery 7 (4%) 2 (2%) 5 (11%) 0 0 0
No treatment 9 (5%) 6 (5%) 3 (6%) 0 0 0
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(7%) patients initially underwent a hemithyroidectomy for a
‘‘benign thyroid tumor’’ and later underwent total thyroid-
ectomy upon being diagnosed with TC due to the manifes-
tation of SMs. Nine (6%) patients with SMs did not receive
any thyroid surgery due to, for example, patient refusal or
high operative risk. 131I ablation was performed in 94% of the
patients with differentiated TC.
Treatment of the SMs. Information about the treatment
for SMs in 183 of the TC patients was available for analysis.
Of those, 67% received surgery, 24% nonsurgical treatment,
4% radiosurgery, and 5% of the patients did not undergo any
of these therapies. Radical surgical treatment, that is, total
removal of the metastatic lesions in the patients with single
isolated SMs, was performed in 16 (13%) of the patients.
Embolization was used in 72 cases (39%), with preoperative
embolization before radical or palliative surgery in 55 (76%)
of those patients. It was the only treatment in 17 (24%) pa-
tients. Radiotherapy was the leading treatment for the pa-
tients who received nonsurgical therapy; it was applied in 39
(87%) of 45 patients. Of the surgical patients, 48 (39%) also
received external radiation.
Tumor type-specific data
FTC. Among the 120 patients with FTC, 66% were fe-
males and 34% were males. Their mean age was 56.7 – 14.4
years. Of those patients, 48% had solitary SMs and 52%
multiple SMs. The distribution of the metastatic lesions fol-
lowed the localization of the radiculomedullary arteries that
supply the spinal cord (Fig. 3A and B). Patients with both
bone non-SMs and solid organ metastases, as well as patients
with bone non-SMs, were more common among the multisite
SMs group. The patients who did not have solid organ me-
tastases and bone non-SMs were more prevalent in the soli-
tary SM group ( p < 0.01). Thus, multiple SMs of the FTC
FIG. 2. Schematic illustration of the presentation of spinal metastases secondary to thyroid carcinoma. In our study, about
35% of spinal metastases presented as an initial manifestation of thyroid cancer; 30% of the patients had synchronous
metastases, and 35% had metachronous metastases. Follicular thyroid cancer was found to be more common in spinal
metastases that manifested thyroid carcinoma, and as metachronous metastases, while papillary thyroid carcinoma was
prevalent in synchronousmetastases ( p < 0.05). Spinal metastases that manifested thyroid carcinoma had the highest incidence
of solitary lesions (49%), while metachronous metastases had the lowest prevalence at 38%. Patients with spinal metastases
that manifested thyroid carcinoma as compared with patients whose spinal metastases were diagnosed at the time of thyroid
surgery or during follow-up had the lowest level of solid organ metastases (35.8%) and the highest level of isolated spinal
metastases (38%), and 26.2% of the patients had spinal metastases and other bone nonspinal metastases. In total, 50% of the
patients with metachronous spinal metastases had accompanying solitary organ metastases; 25% had concomitant bone
nonspinal metastases, and only 25% of the patients with spinal metastases had no other distant metastases. The majority of the
patients (80%) with metachronous spinal metastases had solitary organ metastases, only 10% of the patients had spinal
metastases and other bone nonspinal metastases, and 10% of the patients had isolated spinal metastases ( p< 0.05).
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FIG. 3. Distribution of spinal metastases originated from follicular and papillary thyroid carcinomas. (A) Our analysis
revealed that the distribution of spinal metastases secondary to follicular thyroid carcinoma matches the localization of the
medullary segmental arteries: the number of involved vertebrae was highest at the levels of medullary segmental artery
localization and lowest at the watershed areas. The distribution of spinal metastases secondary to papillary cancer does not
match the localization of the medullary segmental arteries. (B) A possible explanation of the phenomenon in Figure 3A.
Follicular thyroid carcinoma has a tendency to spread hematogenously. Segmental radicular arteries enter the intervertebral
foramina and travel along the nerve roots. Selected anterior radicular arteries form anterior radiculomedular branches,
providing a segmental arterial supply to the spinal cord: the large cervical radiculomedullary artery occurs at level C5–C7;
the upper thoracic segment is generally perfused by a single dominant radiculomedullary artery arising from T4–T5; the
artery of Adamkiewicz is the largest radiculomedullary artery and is most commonly located at T10 on the left side; the
additional radiculomedullary artery of Deproges–Gotteron arises at the L4–L5 level. The segmental arteries (A) divide into
numerous branches at the intervertebral foramen, supplying the bone structures. The segmental arteries that give rise to the
radiculomedullary arteries (B) and (C) are supposed to be larger than the other segmental arteries, and thus blood flow in
these vessels and in their vertebral body branches (D) is higher. The probability of carrying follicular thyroid carcinoma
metastases to the vertebral body is therefore high.
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were associated with significant metastatic involvement of
the solid organs and bones. The FTCGroup S comprised 41%
of the patients, and 59% of the patients were included in the
FTC Group T (Fig. 4). The mean follow-up in this group was
50 months (0–191 months); 59 months for the patients with
solitary SMs and 47 months for the patients with multiple
PTC SMs.
FTC Group S. None of the FTC patients presented with
direct expansion of their tumors to the spine. However, 49%
of the patients had solitary SMs and 51% multiple lesions.
Bone non-SMs were more common ( p < 0.05) in patients
with multisite SMs compared to solitary SMs. There was a
trend ( p = 0.67) for multisite SMs to be associated with solid
organ metastases. Importantly, 68% of the patients with
single-site SM in the FTC Group S did not have any other
distant metastases.
FTC Group T. In Group T, 36% of the patients had
synchronous metastases, and 64% of the patients developed
metachronous metastases within 127.8– 94.6 months (12–
372 months) after TC was diagnosed. Solitary SMs were
found in 47% of the patients, and 53% of the patients had
multiple SMs. Patients with multiple SMs had a significantly
higher risk of developing both bone non-SMs ( p < 0.01) and
solid organ metastases ( p < 0.01). Of the patients with single-
site SM in the FTC Group T, 38% did not have any other
distant metastases.
FTC Group S versus FTC Group T. When we compared
the FTC Group S with the FTC Group T, solid organ me-
tastases were found to be more common in the latter
( p< 0.01). The development of bone non-SMs was not sig-
nificantly different between the groups.
Appearance of distant FTC metastases. Among the 64
patients available for analysis, 52 (81%) patients had the
first distant metastasis localized in the bones (including the
spine). In nine (14%) patients, bone and solid organ meta-
stases developed at the same time, and in three (5%) patients,
distant metastases manifested with solid organ metastases.
This means that, altogether, solid organ metastases were di-
agnosed as the first distant metastases in 19% of the patients,
while 95% of the patients had bone metastases (Fig. 5).
FIG. 4. Spinal metastases from follicular thyroid carcinoma. The initial presentation of follicular thyroid carcinoma as
spinal metastases (Group S) was found in 45% of all the patients in our study. In this group, 49% of the patients had single-
site spinal metastases, and 51% had multiple spinal metastases; a total of 29% of the patients had solid organ metastases,
29% had only bone nonspinal metastases, and 42% had neither bone nonspinal metastases nor solid organ metastases. Spinal
metastases that were identified at the time or developed after TC diagnosis (Group T) comprised 55% of all the patients with
follicular thyroid cancer. In this group, synchronous metastases were found in 36% of the patients: 53% of them had
multiple spinal involvement, 50% had solid organ metastases, 30% had only bone nonspinal metastases, and 20% had
neither bone nonspinal metastases nor solid organ metastases. Metachronous metastases were found in 64% of the patients
in Group T. The majority of the patients (63%) had multilevel spinal involvement: 82% had solid organ metastases, only 9%
had bone nonspinal metastases, and 9% had neither bone nonspinal metastases nor solid organ metastases.
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Our analysis revealed a group of patients who had under-
gone a hemithyroidectomy for a putative thyroid tumor but
had developed SMs years later. It is speculated that those
patients had minimally invasive FTC that was not diagnosed
at the time of surgery. This group consisted of 10 patients, all
of whom were females. They had a mean age of 36.4 – 0.4
years, which meant that they were younger than all the other
FTC patients ( p < 0.001). These metastases also developed
later (221.7 – 138 months) than the other FTC metachronous
metastases (101.5– 68.4 months; p < 0.001). Upon diagnosis
of SMs, all the patients underwent total thyroidectomies and
radioiodine therapy.
Clinical presentation and treatment. The majority of the
patients (72%) presented with symptoms of neuronal struc-
ture compression: either myelopathy (57%) or radiculopathy
FIG. 5. Schematic illustration of characteristics of spinal metastases due to the follicular thyroid cancer and papillary
thyroid cancer. In follicular thyroid cancer, 81% of the patients had the first distant metastasis localized in the bones
(including the spine); 14% of the patients had the initial distant metastases in bone and solid organs; and in 5% of the
patients, the first distant metastases were found in solid organ. In other words, in follicular thyroid cancer, solid organ
metastases were diagnosed as the first distant metastases in 19% of the patients, with a subsequent increase to 48% during
follow-up, while 95% of the patients had bone metastases. Even though all the patients had thyroidectomy following the
initial TC diagnosis, the number of solid organ metastases increased over time. Of the patients with papillary thyroid cancer,
in 64% of the patients, the first distant metastasis in the bone; 31% of the patients had the initial metastases localized in the
bone and solid organs; and in 5%, the first distant metastases were found in solid organ. This means that solid organ
metastases as the first distant metastases were found in 36% patients, and this number progressed to 42%, while 95% of the
patients had bone metastases. It seems that little if no solid metastatic progression was seen.
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(15%). Back pain was the initial symptom in 23% of the
patients. Only 5% of the patients were asymptomatic. In
66%, the SMs lesions were 131I avid, while in 34%, they
were not. Surgery was performed for 72% of the patients, and
nonsurgical treatments were provided for 18%. Radiosurgery
was used for 2% of the patients, and 5% received no treatment.
PTC
Of the 54 patients with PTC, 55% were male and 45%
female. The mean age was 57.8 – 13.9 years with a trend
showing the males to be older than the females (61– 10.0
years vs. 54.5– 17 years respectively; p = 0.066). Within the
PTC group, 46% of the patients had solitary SMs with 54%
having multiple SMs. All the PTC patients with solitary SMs
were significantly older than those with multiple lesions
(64 – 11.7 years vs. 51.4 – 14 years respectively; p < 0.001).
Among the patients with PTC solitary SMs, 53% did not have
any other metastases. Only 24% of the PTC patients had SMs
on presentation of TC (the PTC Group S), while the other
76% were found to have SMs at the time of TC diagnosis or
after TC was diagnosed (the PTC Group T; Fig. 6). The mean
follow-up for the PTC patients was 38 months (0–139
months), 34 months for the patients with solitary SMs, and 48
months for those with multiple PTC SMs.
PTC Group S. The mean age of the 10 patients in the
PTC Group S was 63– 14 years. There was no significant
difference in the distribution of the bone non-SMs and solid
organ metastases between the patients with solitary and
multiple SMs. Three of the 10 patients had direct expansion
of their tumors to the spine. Those three patients were sig-
nificantly older than those in the PTC Group T (68 – 7.4 years
vs. 55– 15.3 years respectively; p = 0.03). Importantly, 67%
of the patients with single-site SMs in the PTC Group S did
not have any other distant metastases.
PTC Group T. In PTC Group T, 76% of the patients were
found to have SMs at the time of TC diagnosis or to have
developed SMs after TC diagnosis. Synchronous SMs were
found in 20 (63%) patients, and metachronous SMs were
evident in 12 (37%) patients within 34 months (0.5–144
FIG. 6. Spinal metastases from the papillary thyroid carcinoma. The initial presentation of papillary thyroid carcinoma as
spinal metastases (Group S) was found in 24% of all the patients. In this group, 64% of the patients had single-site
metastases and 36% had multilevel spinal involvement; 46% of the patients had solid organ metastases, 8% had other bone
nonspinal metastases, and 46% had neither bone nonspinal metastases nor solid organ metastases. The majority of the
patients with papillary thyroid cancer (76%) constituted Group T, whose spinal metastases were found at the time or
developed after TC diagnosis. In this group, synchronous metastases were found in 63% of the patients: half of them had
multiple spinal involvement, 40% had solid organ metastases, 27% had other bone nonspinal metastases, and 33% had
neither bone nonspinal metastases nor solid organ metastases. Metachroneous metastases were found in 37% of the patients
of Group T. The majority of the patients in this group (87%) had multilevel spinal involvement, 80% had solid organ
metastases, and only 20% had other bone nonspinal metastases.
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months) after TC surgery. Among the patients with single-
site SMs in FTC Group T, 43% did not have any other distant
metastases.
PTC Group S versus PTC Group T. There were no sig-
nificant differences in the distribution of bone non-SMs and
solid organ metastases between the patients of PTC Group S
and PTC Group T.
Appearance of distant PTC metastases. Among the 36
patients available for analysis, 64% had initial distant bone
metastases, 31% presented with bone and solid organ meta-
stases at the same time, and 5% had initial solid organ meta-
stases. Thismeans that, altogether, solid organmetastaseswere
diagnosed as first distant metastases in 36% of the patients,
while 95% of the patients had bone metastases (Fig. 4).
Clinical presentation and treatments. A total of 28% of
the patients presented with myelopathy (with or without radi-
culopathy), 9%with radiculopathy only, 25%of the patients had
back pain as an initial symptom, and 38% of the patients were
asymptomatic. Of the patients with PTC lesions, 43% were 131I
avid, while 57% did not show an uptake of radioiodine. In-
formation regarding treatment was available for 47 patients.
Surgery was performed for 55% of the patients, nonsurgical
treatments were provided for 28%, radiosurgery was used for
11% of the patients, and 6% did not receive any therapy.
FTC versus PTC
A comparative analysis of the patients with FTC and PTC
revealed specific features (Table 2). Among the patients with
FTC, females predominated (66%), while for PTC, males
were in the majority (55%; p < 0.02). SMs were a presenting
symptom in FTC patients (41%) more often, while PTC SMs
were more commonly identified after TC had been diagnosed
(76%; p < 0.05). Among the Group T patients, PTC presented
more frequently with synchronous metastases (63%), while
FTC was associated with metachronous metastases (64%;
p < 0.01). The mean period until establishing a diagnosis of
SMs after the initial TC diagnosis in Group T was 82– 37.4
months for FTC and 35 – 17.2 months for PTC ( p< 0.01).
In the FTC Group S, solid organ metastases were less
common than in FTC Group T ( p< 0.01). Multisite FTC SMs
were more frequently associated with the development of
other bone non-SMs compared to solitary SMs ( p < 0.01),
although there were no such associations for PTC.
First FTC distant metastases were diagnosed more often
within bone, but initial solid organ metastases and bone
metastases at the same time were found more commonly in
patients with PTC ( p < 0.05).
In the patients with FTC, solid organ metastases were di-
agnosed as the first distant metastasis in 19% of the patients
and progressed to 48% on follow-up, while 95% of the pa-
tients had bone metastases. Among the PTC patients, 36%
had solid organ metastases as the first distant metastases, and
this increased to 42% on follow-up, while 95% of the patients
had bone metastases ( p < 0.05; Fig. 5).
The FTC patients presented with SMs with myelopathy or
radiculopathy, while those patients with PTC either showed
evidence of back pain or were asymptomatic ( p< 0.01).
The patients with FTC vertebral lesions took up 131I more
often than those with PTC SMs ( p < 0.01). Surgery was
performed significantly more frequently for patients with
FTC SMs, while nonsurgical treatment was more commonly
used for patients with PTC SMs ( p < 0.05).
MTC, HTC, and ATC
Of all the patients in the cohort, nine patients hadMTC, six
had HCC, and two had ATC. A summary of the patients’ data
is shown in Table 1. Because of their rarity, a comparative
statistical analysis was not feasible.
Discussion
The first description of TC SMs was provided by Max
Runge in Virchov’s Archive in March 1876. He described a
Table 2. Comparison of Demographic Characteristics of Spinal Metastases
from Follicular and Papillary Thyroid Cancer
Follicular thyroid cancer Papillary thyroid carcinoma p-Value
Gender Females Males <0.02
Clinical manifestation Spinal metastases presented as an initial
manifestation of thyroid cancer
Spinal metastases presented after
thyroid cancer diagnosis
<0.05
Type of metastases after
thyroid cancer diagnosis
Synchronous metastases Metachronous metastases <0.01
Mean time of developing
SMs in Group T
82.1 months 35.3 months <0.01
Group S vs. Group T Solid organ metastases were less common
in Group S than in Group T ( p < 0.01)
No correlation found
Multisite vs. single-site SMs Multisite SMs were associated with bone
nonspinal metastases, as compared to
solitary SMs ( p < 0.01)
No correlation found
First distant metastases Bone (81%) Bone and solid organ
metastases (31%)
<0.05
Clinical presentation Neural structures compression (71.9%) Back pain (25.5%)
Asymptomatic (38.3%)
<0.01
Radioiodine uptake Positive (65.8%) Negative (57.1%) <0.01
Treatment applied Surgical (71.6%) Nonsurgical (27.7%) <0.05
1496 KUSHCHAYEVA ET AL.
41-year-old woman with severe neck pain who progressed to
paralysis and death. An autopsy revealed a C1–C2 tumor
compressing the spinal cord that histologically resembled
thyroid tissue (62). Seven months later, Cohnheim published
Simple Colloid Goiter with Metastases. He described the post-
mortem examination of a patient with multiple tumors in the
lungs, bronchial glands, spine, and femur, which resembled
goiter, with nodules of the same appearance in the thyroid
gland. Cohnheim noted that this growth could not be regarded
as cancerous, and it was described as ‘‘benign metastasizing
goiter’’ (63). In 1926, Simpson thoroughly reviewed 77 re-
ported cases (including 25 with vertebral involvement) along
with three of his own cases. He concluded that these entire
osseous lesions, which resembled normal thyroid tissue, were
actually metastases from an original thyroid cancer. Since the
initial publication by Max Rouge in 1876, to our knowledge,
no specific review devoted to the comprehensive analysis of
SMs has been published.
Demographics of TC SMs
The relative incidence of PTC is higher (80%) than that of
FTC (15%), but bonemetastases are more frequent in patients
with FTC compared to those with PTC at 7–28% and 1–7%
respectively (64–68). As in other studies, we found SMs to
be more common in FTC than PTC patients (64,69). More-
over, patients with FTC are usually older at the time of initial
thyroid surgery (70). However, the mean age of the patients
from our groups with SMs at PTC and FTC diagnosis were
57.8 – 14 years and 56.7– 14.4 years respectively, without
differences in histological type, indicating that SMs may be a
later event in patients with PTC. This age difference is con-
sistent with other studies and may be attributed to a more
aggressive form of TC that is associated with metastatic
disease and reduced survival (64,71–75).
Our male cohort constituted 41% of the patients. Other
studies also showed a significant proportion of males with TC
bone metastases (35–67%) compared to the male–female
ratio seen in TC where females predominate. In contrast to
those with FTC, among the patients with PTC, males pre-
dominated, which may indicate that sex is a risk factor for the
development of PTC SMs. Furthermore, the males with PTC
tended to be older than the females.
The most common mechanism for FTC metastatic spread
is via a hematogenous route compared to the lymphatic
spread of PTC (76). The propensity for axial skeleton SMs
is thought to be secondary to blood flow distribution.
Moreover, bone is a large repository for growth factors,
which may assist in the propensity for bone seeding (68).
We have demonstrated that the distribution of the FTC SMs
matches the localization of the medullary segmental ar-
teries (77,78).
Given that solitary SMs are found in roughly half the pa-
tients with SMs, perhaps a quarter of PTC and FTC patients
with SMs can be considered for radical spinal surgery or
radiosurgery to ensure the complete removal/destruction of
metastatic tumor tissue with the intention of improving
quality of life and potentially increasing survival. Certainly,
patients with thyroid SMs are always at risk for additional
bone or lung metastases in later years. Therefore, radical
surgery or the radiosurgery of isolated SMs cannot be con-
sidered as curative treatments. However, utilizing these
methods for patients with solitary thyroid SMs may poten-
tially significantly prolong progression-free survival rates.
Moreover, those patients with TC who manifest with
single-site SMs have a significantly lower probability of
solid organ metastases compared to those who had SMs
at the time of TC diagnosis or who developed TC during
follow-up. The patients may initially present to a number of
different medical specialties, such as neurology, orthope-
dics, neurosurgery, or general medicine (20). After an initial
vertebral biopsy of the affected vertebra and confirmation of
thyroid SMs, comprehensive imaging for the identification
of other asymptomatic metastatic sites is important. For
patients with SMs without bone non-SMs and solid organ
metastases, radical treatment, that is, radiosurgery for lo-
calized vertebral lesions and total en-bloc spondylectomy
for extended vertebral metastases, can be used. It seems that
in the confirmed cases of thyroid SMs, when urgent surgery
is required, the radical spinal surgery technique is prefera-
ble, since such patients have a relatively high chance of not
having solid organ metastases.
Appearance of distant TC metastases
As previously shown, in terms of FTC, solid organ me-
tastases were diagnosed as the first distant metastases in 19%
of the patients in our study, with a subsequent increase to 48%
during follow-up, while 95% of the patients had bone me-
tastases. Even though all the patients had TC removal fol-
lowing the initial diagnosis of the disease, the number of solid
organ metastases increased over time. In the case of PTC,
36% of the patients had solid organ metastases as the first
distant metastases, and this number progressed to 42%, while
95% of the patients had bone metastases. It seems that little if
no solid metastatic progression is seen. A large study on bone
metastases—not only on spinal metastasis—is required to
clarify metastatic progression.
Clinical presentation and treatments
Among all the patients with SMs, nearly 35% had an initial
presentation of TC, whereas 65% were identified after TC
diagnosis. According to our data, the FTC patients with SMs
as an initial presentation had a significantly lower rate of solid
organ involvement compared to Group T. The same was not
evident for PTC patients. Accordingly, the patients with FTC
had less advanced disease, and there was no age difference in
comparison to the PTC patients. Bernier et al. also showed
that patients who had signs of bone metastases as initial
symptoms of TC had significantly higher survival rates (79).
In our study, SMs after TC diagnosis were almost equally
divided between synchronous (46%) and metachronous me-
tastases (54%). A similar distribution (50%/50%) was found
by Zetting et al. for all bone metastases (1). To assess the
distribution of SMs from FTC and PTC in this subgroup more
precisely, we analyzed the synchronous and metachronous
metastases in the patients in our study separately. The mean
time for developing SMs in these patients was 35.3 months
for PTC and 82.1 months for FTC. PTC often presented with
synchronous metastases, while FTC mostly presented with
metachronous metastases up to 372 months following the
initial TC diagnosis. A heightened index of suspicion is a key
element in the early evaluation and diagnosis of any patient
with a history of TC.
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Within our patient population, we identified a cohort of 10
women with FTCwho had been operated on many years prior
for seemingly benign thyroid lesions, and these patients later
developed SMs. We can speculate that these patients had
undiagnosed FTC microcarcinomas at the time of their
original surgeries. These patients were considerably younger
than the other FTC patients (36.4 – 0.4 years vs. 56.7 – 14.4
years respectively) and their metastases developed sig-
nificantly later than those with other FTC metachronous
metastases (221.7 – 138 months vs. 101.5 – 68.4 months re-
spectively). With respect to the clinical presentation of thy-
roid SMs, the most commonly reported spinal symptoms
were signs of direct neural structure compression, including
myelo- and radiculopathy (67% of the patients), and back
pain (28%). The patients with FTC presented with SMs ac-
companied by symptoms of neural structure compression,
while the PTC patients were more likely to present with back
pain or to be asymptomatic.
In our study, only 57.8% of all TC lesions were 131I avid,
while other studies showed the range to be 43–73%
(74,79,80). In our analysis, 65.8% of the FTC and 42.9% of
the PTC vertebral lesions were 131I avid. However, the effect
and significance of radioiodine therapy on SMs and its con-
tribution is difficult to assess based on the existing literature.
Our data may be biased because only lesions that we could
clearly distinguish on scans were evaluated. Two-thirds
(66.7%) of the patients in our study underwent surgery. Be-
cause FTC presented with symptoms of neural structure
compression more often, surgery was used significantly more
frequently for FTC than PTC patients. Radiosurgery, which
has been shown to control tumor growth and palliate tumor-
induced back pain, was used in 4.9% of the patients. External
radiation was applied in 87% of the patients who received
conservative treatment.
Conclusions
1. A significant proportion of TC patients with single-le-
vel SMs do not have any other distant metastases and
may be considered for radical treatment.
2. Patients with SMs due to FTC who manifest TC have a
better prognosis than those who develop SMs after TC
diagnosis.
3. TC SMs may occur up to 372 months after the original
TC diagnosis, which emphasizes the need for the long-
term follow-up of patients with TC.
4. SMs originating from FTC and PTC appear to have
distinct presentations, behaviors, and treatment mo-
dalities and should be categorized separately for treat-
ment and follow-up planning.
5. The treatment of SMs requires a multidisciplinary ap-
proach that includes endocrine medical and surgical
specialists, radiologists, and oncologists, in order to
implement radical treatment methods (such as 131I, total
en bloc spondylectomy, and radiosurgery) if possible.
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